Australian biotech Opthea (Nasdaq: OPT) is cutting around two-thirds of its workforce, as the company moves to curb spending ...

Opthea’s staff are paying for its clinical failures. Days after back-to-back flops sank an eye disease asset, the biotech ...

and Novartis hopes it will appeal to doctors as this means cost per patient is lower compared with Lucentis and Bayer/Regeneron’s rival, Eylea (aflibercept). But there are concerns that doctors ...

The FDA has approved Susvimo for the treatment of people with wet AMD who have previously responded to at least two anti-VEGF drugs such as Lucentis or Bayer and Regeneron's rival Eylea (aflibercept).

Emergen Research Logo The development of anti-VEGF therapies, which inhibit the growth of abnormal blood vessels in the retina, reduces the ...

Nuno Mendes struck in stoppage-time to cement PSG’s control of their Champions League quarter-final tie with a 3-1 win over Aston Villa in Paris.. It was Unai Emery’s side, though, who took a ...

For years, T-Mobile has been the third-largest US carrier, and the Sprint merger only solidified its position. These days T-Mobile is every bit as important as Verizon and AT&T, arguably more so ...

The Galaxy S25 Ultra is by far the best Galaxy Ultra flagship released so far, with top performance, a design that's fresher than ever, top-notch hardware, and one of the top cameras in an Android ...

We may earn a commission if you make a purchase from the links on this page. The Galaxy Plus model has always been the "middle child" of the lineup, offering a slightly larger screen and battery ...

The approval makes ILM-Blue the first DORC posterior dye product available in China, according to a press release from Zeiss.